The content of this website is intended for United States audiences only.

Global Share

STATUS Available

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

LAST UPDATED

January 10 2025

Clinicaltrials.gov ID

NCT05776134

OVERVIEW

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

PROTOCOL SUMMARY

The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release.

View More

Participation Requirements

Calendar

Age

18 Years +

Condition

Sex

ALL

Healthy Icon

Healthy Volunteers

No

Study Details

Medical Condition

Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia

Gender

N/A

Date

Study Type

EXPANDED_ACCESS

Study Phase

Product

Brexucabtagene Autoleucel

Eligibility Information

Inclusion

Inclusion Criteria

  • Have commercially manufactured brexucabtagene autoleucel that does not meet commercial release criteria but does meet Kite clinical trial release criteria
  • Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been post-menopausal for at least 2 years are not considered to be of childbearing potential)
  • Deemed medically fit and stable to receive the product per the investigator's evaluation
  • Repeat leukapheresis is not feasible per the investigator's assessment
  • Be diagnosed with 1 of the approved labeled indications for brexucabtagene autoleucel that is intended for release
  • In the Investigator's opinion, there is no satisfactory alternative therapy available to the individual
VIEW MORE
Exclusion

Exclusion Criteria

  • History of severe immediate hypersensitivity to any drugs or metabolites of similar chemical classes as brexucabtagene autoleucel
  • Uncontrolled active infection or inflammation per physician assessment
  • Primary central nervous system (CNS) lymphoma
VIEW MORE

Locations

Locations (44)
Available

University of Alabama at Birmingham

Birmingham, Alabama, United States, 35234

Available

Banner MD Anderson Cancer Center

Gilbert, Arizona, United States, 85234

Available

City of Hope

Duarte, California, United States, 91010

Available

Colorado Blood Cancer Institute

Denver, Colorado, United States, 80218

Available

Mayo Clinic Jacksonville

Jacksonville, Florida, United States, 32224

Available

Winship Cancer Institute

Atlanta, Georgia, United States, 30322

Available

Northside Hospital

Atlanta, Georgia, United States, 30342

Available

St. Luke's Cancer Institute

Boise, Idaho, United States, 83712

Available

Northwestern Memorial Hospital

Chicago, Illinois, United States, 60611

Available

The University of Kansas Medical Center

Westwood, Kansas, United States, 66205

Available

University of Maryland Cancer Center

Baltimore, Maryland, United States, 21201

Available

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Available

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Available

Dana Farber Cancer Institute - Chestnut Hill

Boston, Massachusetts, United States, 02215

Available

University of Michigan

Ann Arbor, Michigan, United States, 48109

Available

Mayo Clinic

Rochester, Minnesota, United States, 55902

Available

Washington University School of Medicine- Siteman Cancer Center

Saint Louis, Missouri, United States, 63110

Available

University of Nebraska Medical Center

Omaha, Nebraska, United States, 68198

Available

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

Available

Montefiore Medical Center (MMC)

Bronx, New York, United States, 10467

Available

Roswell Park Cancer Institute

Buffalo, New York, United States, 14263

Available

Weill Cornell Medicine - NewYork-Presbyterian Hospital

New York, New York, United States, 10021

Available

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

Available

University of Rochester Medical Center

Rochester, New York, United States, 14642

Available

UNC Hospitals, The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States, 27514

Available

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Available

The Ohio State University

Columbus, Ohio, United States, 43201

Available

Oregon Health & Science University

Portland, Oregon, United States, 97239

Available

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Available

Fox Chase Cancer Center

Philadelphia, Pennsylvania, United States, 19111

Available

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States, 15232

Available

Avera Cancer Institute

Sioux Falls, South Dakota, United States, 57105

Available

Sarah Canon Research Institute

Nashville, Tennessee, United States, 37203

Available

Tennessee Oncology

Nashville, Tennessee, United States, 37203

Available

Vanderbilt-Ingrim Cancer Center

Nashville, Tennessee, United States, 37232

Available

Baylor University Medical Center

Dallas, Texas, United States, 75246

Available

Houston Methodist Hospital

Houston, Texas, United States, 77030

Available

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Available

Methodist Healthcare System of San Antonio dba Methodist Hospital

San Antonio, Texas, United States, 782229

Available

Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, United States, 84112

Available

Virginia Commonwealth University

Richmond, Virginia, United States, 23298

Available

Fred Hutchinson Cancer Center

Seattle, Washington, United States, 98109

Available

West Virginia University

Morgantown, West Virginia, United States, 26506

Available

Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53227